Certain type 2 diabetes drugs promote weight loss, but how they do this remains poorly understood. Insight into how these drugs work in the body -- and especially the brain -- could help create new drugs that effectively control body weight. In an important advance on that front, a new study shows that these drugs, called glucagon-like peptide-1 receptor agonists (GLP-1RAs), reduce body mass by targeting a different part of the brain than previously thought.